Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab, Varlilumab, and Radiation in Metastatic NSCLC
NCT04081688Phase 1Terminated
- Sponsor
- Rutgers University
- Start
- Sep 2019
- Primary completion
- Apr 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of varlilumab in non-small cell lung cancer (NSCLC), sponsored by Rutgers University. Primary endpoint: Number of Participants With Grade 3 and 4 Toxicity. Started Sep 2019; status: terminated.
02
Drugs
varlilumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04081688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081688.